

Video Article

Methods for the Determination of Rates of Glucose and Fatty Acid Oxidation in the Isolated Working Rat Heart

Bhavisha Bakrania¹, Joey P. Granger¹, Romain Harmancey¹

¹Department of Physiology and Biophysics, Mississippi Center for Obesity Research, Cardiovascular-Renal Research Center, University of Mississippi Medical Center

Correspondence to: Romain Harmancey at rharmancey@umc.edu

URL: <https://www.jove.com/video/54497>

DOI: [doi:10.3791/54497](https://doi.org/10.3791/54497)

Keywords: Biochemistry, Issue 115, Heart perfusion, working heart, cardiac function, metabolism, glucose oxidation, fatty acid oxidation, radioisotopes

Date Published: 9/28/2016

Citation: Bakrania, B., Granger, J.P., Harmancey, R. Methods for the Determination of Rates of Glucose and Fatty Acid Oxidation in the Isolated Working Rat Heart. *J. Vis. Exp.* (115), e54497, doi:10.3791/54497 (2016).

Abstract

The mammalian heart is a major consumer of ATP and requires a constant supply of energy substrates for contraction. Not surprisingly, alterations of myocardial metabolism have been linked to the development of contractile dysfunction and heart failure. Therefore, unraveling the link between metabolism and contraction should shed light on some of the mechanisms governing cardiac adaptation or maladaptation in disease states. The isolated working rat heart preparation can be used to follow, simultaneously and in real time, cardiac contractile function and flux of energy providing substrates into oxidative metabolic pathways. The present protocol aims to provide a detailed description of the methods used in the preparation and utilization of buffers for the quantitative measurement of the rates of oxidation for glucose and fatty acids, the main energy providing substrates of the heart. The methods used for sample analysis and data interpretation are also discussed. In brief, the technique is based on the supply of ¹⁴C- radiolabeled glucose and a ³H- radiolabeled long-chain fatty acid to an *ex vivo* beating heart via normothermic crystalloid perfusion. ¹⁴CO₂ and ³H₂O, end byproducts of the enzymatic reactions involved in the utilization of these energy providing substrates, are then quantitatively recovered from the coronary effluent. With knowledge of the specific activity of the radiolabeled substrates used, it is then possible to individually quantitate the flux of glucose and fatty acid in the oxidation pathways. Contractile function of the isolated heart can be determined in parallel with the appropriate recording equipment and directly correlated to metabolic flux values. The technique is extremely useful to study the metabolism/contraction relationship in response to various stress conditions such as alterations in pre and after load and ischemia, a drug or a circulating factor, or following the alteration in the expression of a gene product.

Video Link

The video component of this article can be found at <https://www.jove.com/video/54497/>

Introduction

Clinical Relevance

In the mammalian heart, there is a strong positive relationship between the flux of substrates through oxidative metabolic pathways, ATP generation and cardiac work¹. Over the past two decades, the investigation of the intricate link between cardiac metabolism and function has led to recognize that alterations in cardiac metabolism are a cause for contractile dysfunction and possibly pathological structural remodeling in the setting of different types of heart disease²⁻⁴. Therefore, it is expected that our understanding of the mechanisms governing metabolic remodeling of the stressed heart will lead to the identification of therapeutic targets for the prevention or treatment of heart failure⁵⁻⁷. The recent publication of a scientific statement from the American Heart Association on "Assessing Cardiac Metabolism" emphasizes the growing interest of the scientific community for this field of research⁸. But while the technological advances in cardiac imaging now allow for a rapid and accurate evaluation of cardiac morphology and function, the *in vivo* study of cardiac metabolism remains limited and burdensome: Nuclear Magnetic Resonance (NMR) spectroscopy and Positron Emission Tomography (PET) imaging can be used to follow cardiac high energy phosphate metabolism and Krebs cycle activity, but these techniques are plagued by high operating costs and by their inability to determine the contribution of various substrates to oxidative metabolism in steady-state conditions⁹. To this date the *ex vivo* working heart preparation represents the sole and unique technique available to study, simultaneously and in real time, contractile function and flux of substrates into oxidative metabolic pathways^{7,9}. The following protocol aims to provide guidelines in the preparation and utilization of reagents used to determine the rates of substrates utilization in the isolated working rat heart.

The Isolated Working Rodent Heart Apparatus

Although the technique is almost half a century old, the isolated working rat heart preparation remains a method of choice for cardiovascular research. As with the Langendorff heart preparation, the working rodent heart offers a relatively simple, reliable, and inexpensive way to measure a wide range of cardiac parameters independently from the confounding effects of other organs, neurohormonal and other circulating factors. But in contrast to the Langendorff-perfused heart, the working heart continues to perform near-physiological cardiac work, a prerequisite for the generation of oxidative metabolic flux to levels that are relevant to *in vivo* conditions. This is achieved by delivering the perfusion buffer to

the left ventricle (LV) via a cannula connected to the left atrium, and as the LV fills and contracts, the buffer is ejected through the aortic line against a determined afterload hydrostatic pressure. The design of the perfusion apparatus originally described by Neely and colleagues¹⁰ was subsequently improved by Taegtmeier, Hems and Krebs¹¹, but has changed very little ever since. As described in the original apparatus, contractile function can be assessed through determination of cardiac output, using no more than graduated cylinders and a stopwatch to measure aortic and coronary flows^{10,11}. Several vendors now offer complete working rodent heart perfusion systems. These commercially available apparatus can be acquired with flowprobes, pressure transducers, a pressure-volume catheter and all the equipment necessary for cardiac functional data acquisition and analysis. The vendors provide extensive documentation and training sessions to familiarize the new user with their equipment. Several review articles also detail protocols on the working heart instrumentation and on the use of catheters to measure cardiac function in rodents¹²⁻¹⁵. For this reason, we will only briefly mention the set-up of the perfusion apparatus and the recording equipment. The present protocol rather aims to complement the already available information with a description of the methods that can be implemented to simultaneously measure the rates of glucose and long-chain fatty acid oxidation, the two major energy providing substrates in the normal heart. We describe here all the steps involved in the use of radiolabeled energy substrates for the assessment of myocardial oxidative metabolism, from the preparation of reagents and buffers to the recovery and processing of samples, to the data analysis.

Principles of the Method

Cardiomyocytes generate the bulk of their energy for contraction from the oxidative phosphorylation of fatty acids (principally long-chain fatty acids) and carbohydrates (glucose and lactate). The heart has very limited energetic reserves and relies on a constant supply of these energy providing substrates from the circulation. The catabolism of glucose through the glycolytic pathway yields pyruvate which is then decarboxylated by the pyruvate dehydrogenase complex of the inner mitochondrial membrane. Long-chain fatty acids, extracted from circulating albumin or lipoprotein triglycerides, are first activated into acyl-CoA molecules in the cytosol and subsequently transported inside the mitochondrial matrix through the carnitine shuttle to enter the beta-oxidation pathway. The acetyl-CoA molecules produced by the catabolism of glucose and fatty acids fuel the Krebs cycle to generate the reducing equivalents (NADH and FADH₂) which are used by the electron transport chain to build the proton-motive force across the inner mitochondrial membrane and generate ATP through the activity of the ATP synthase. Water and carbon dioxide are the end byproducts of the enzymatic reactions taking place inside the Krebs cycle. The supply of ¹⁴C- and ³H- radiolabeled substrates (such as ¹⁴C-radiolabeled glucose and ³H-radiolabeled oleic acid) to the isolated working heart will consequently lead to the production of ¹⁴CO₂ and ³H₂O which can be quantitatively recovered from the coronary effluent. The collection of ¹⁴CO₂ is carried out by keeping the isolated perfused heart into a sealed chamber and by immediately recovering the coronary effluent as it exits the heart. A small anion exchange column is used to separate and recover ³H₂O from the coronary effluent. The radioactivity from the processed samples is measured with a liquid scintillation counter, and with knowledge of the specific activity of the radiolabeled substrates used, it is then possible to individually quantitate the flux of glucose and fatty acid in the oxidation pathways^{16,17}.

Protocol

NOTE: All animal procedures were performed according to the NIH Public Health Service Policy on the Human Care and Use of Animals and were approved by the Institutional Animal Care and Use Committee of the University of Mississippi Medical Center. All procedures involving the use of radioisotopes were approved and performed according to the guidelines set by the radiation safety office of the University of Mississippi Medical Center.

1. Preparation of Stock Buffer Solutions and Reagents

1. Krebs-Henseleit (KH) Buffer Stock Solutions
 1. Prepare 2 L of a 20x concentrated salt stock solution containing (in mol/L) 2.37 NaCl, 0.0948 KCl, 0.0236 KH₂PO₄, and 0.0236 MgSO₄·7H₂O. Filter on a 0.45 µm pore size filtration unit and store at room temperature for up to 1 month.
 2. Prepare 2 L of a 20x concentrated (0.5 mol/L) solution of NaHCO₃. The solution can be stored at room temperature for an indefinite period of time.
 3. Prepare 250 ml of a 1 mol/L stock solution of CaCl₂. Filter on a 0.45 µm pore size filtration unit and store at room temperature for up to 1 month.
2. Conversion of Anion Exchange Resin from the Chloride Form to the Hydroxide Form
 1. Wash the anion exchange resin by resuspending it in 1 L ultrapure water. Allow the resin to settle and pour off the excess water. Repeat this step 4 more times.
 2. Pour the resin in a glass microanalysis vacuum filter holder mounted on a filtering flask.
 3. Convert the resin to the hydroxide form by slowly passing through 22 volumes of 1 N NaOH. Mix the slurry intermittently with a stainless steel spatula.
 4. Wash the resin with ultrapure water until the pH falls below 9.0. Check the pH regularly by dipping a pH test strip near the surface of the resin slurry. Cover and store the resin with ultrapure water into a borosilicate glass bottle and protect from light. Do not allow the resin to dry before use.

NOTE: When stored properly, the resin will last at least 3 months.
3. Oleic Acid-albumin 8x Concentrated Stock Solution
 1. In a 4 L Erlenmeyer flask, mix 200 ml of the 20x concentrated salt stock solution and 200 ml of the 20x concentrated NaHCO₃ solution with 3.6 L ultrapure water.
 2. Using a gas dispersion tube with a fritted cylinder, gas the solution for 15 min with a mixture of carbon dioxide 5% and oxygen 95% to stabilize the pH.
 3. Pour 470 ml buffer in a 1 L glass beaker. Add 8.75 ml of the 1 mol/L CaCl₂ stock solution to the 3530 ml buffer remaining in the 4 L Erlenmeyer flask and set aside.
 4. Add 40 g of fatty acid-free BSA to the 1 L glass beaker and stir with a stir bar until dissolved.

5. In a 15 ml conical tube, prepare 4 ml of a 50% (v:v) ethanol solution in ultrapure water. Add 487 mg sodium oleate and vortex until the powder is fully dissolved.
NOTE: Some investigators use palmitic acid instead of oleic acid in the perfusion buffer. A palmitic acid-albumin stock solution may be prepared following the same procedure. However, it is recommended to warm the solution at 70 °C to achieve complete solubilization of sodium palmitate.
6. Add the oleate solution dropwise to the fatty acid-free BSA solution under constant stirring and wait 10 more min for the oleic acid-BSA complex to form.
NOTE: The solution should have a light yellow color and be devoid of visible particles. Presence of a precipitate or insoluble particles may indicate incomplete conjugation of the fatty acid to BSA. If this happens, the solution should be discarded and the process started over again.
NOTE: Palmitate will precipitate if it is allowed to sit in a pipette and cannot be added dropwise. The stirred solution of BSA may be warmed at 37 °C to facilitate binding of palmitic acid. Do not overheat as this may cause denaturation and aggregation of BSA.
CAUTION: The next steps of this protocol involve the manipulation of radioactive material. Wear appropriate PPE and follow the safety and waste disposal regulations set by the institution's radiation safety office.
7. Add 160 µl (0.8 mCi) [9,10-³H]oleic acid to the stirring solution of oleic acid-BSA and stir for another 10 min.
8. Add 2.5 ml of the 1 mol/L CaCl₂ stock solution to the stirring solution of oleic acid-BSA.
9. Cut approximately 1.2 m dialysis membrane tubing and rinse both inside and outside with tap water. Scrub the dialysis tubing vigorously under tap water for 10 to 15 min to remove the glycerol coating of the membrane. Alternatively, remove the coating by soaking the dialysis tubing in warm water for 1 hr before use. Finish by rinsing the dialysis tubing with ultrapure water.
10. Securely tie off one end of the dialysis tubing. Fill with the oleic acid-BSA solution and tie off the other end of the dialysis tubing.
11. Place the filled dialysis tubing into the 4 L Erlenmeyer flask of KH buffer and allow dialyzing overnight at 4 °C under gentle stirring with a stir bar.
12. The next day, remove the 8x concentrated oleic acid-BSA solution from the dialysis tubing. Use the oleic acid-BSA solution immediately for perfusion or aliquot and store at -20 °C. Frozen aliquots are stable for at least 2 months. Avoid multiple freeze-thaw cycles as this may compromise the solubility of the oleic acid-BSA complex.
NOTE: Use only ultrapure water (Resistivity of 18.2 MΩ.cm at 25 °C, total organic carbon <10 ppb, micro-organisms ≤ 1 CFU/ml, particulates with size over 0.22 µm ≤ 1/ml) to prepare the reagents and buffers used for heart perfusion. Conversion of the anion exchange resin from its chloride form to the hydroxide form can be avoided by direct purchase of the hydroxide form at an additional expense (see **Materials Table**). Besides oleate or palmitate, any other type of naturally occurring fatty acid can also be used, as long as a tritiated version of the fatty acid is available to follow its oxidation.

2. Preparation of the Perfusion Buffer

1. In a 4 L Erlenmeyer flask, mix 200 ml of the 20x concentrated salt stock solution and 200 ml of the 20x concentrated NaHCO₃ solution with 3.6 L ultrapure water. Gas the solution for 15 min with a mixture of carbon dioxide 5% and oxygen 95%, and then add 10 ml of the 1 mol/L CaCl₂ stock solution to set the concentration of free Ca²⁺ at 2.5 mmol/L.
CAUTION: The following steps involve the manipulation of radioactive material. Wear appropriate PPE and follow the safety and waste disposal regulations set by the institution's radiation safety office.
2. Transfer 1.750 L KH buffer to a 2 L borosilicate glass bottle. Add 250 ml of the 8x concentrated oleic acid-BSA solution, 1.802 g D-glucose, 400 µl insulin at 0.4 U/ml, and 200 µl (0.2 mCi) [U-¹⁴C]Glucose. Invert bottle to mix. This will give 2 L of complete perfusion buffer containing oleic acid (0.4 mmol/L), D-glucose (5 mmol/L), and insulin (40 µU/ml).
NOTE: A volume of 2 L is sufficient to perfuse a working adult rat heart in non-recirculating conditions for at least 60 min.
3. Use some of the non-radioactive KH buffer to fill two dissection dishes and place on ice to cool.

3. Preparation of the Perfusion Apparatus

NOTE: The investigator can choose to use a custom-built perfusion apparatus such as the one described by Taegtmeier, Hems and Krebs¹¹, or one of the commercially available systems. Perfusion systems are typically composed of the elements described in **Figure 1** below. Besides the tubing and glassware, the rest of the recording equipment is optional and its utilization will depend on the investigator's needs to address the experimental question being asked. Nonetheless, we recommend the use of oxygen microelectrodes to determine the O₂ concentration in the buffer entering and exiting the coronary circulation (**Figure 1**). This will help the investigator control that the heart is supplied with an appropriate amount of oxygen, and that the oxygen supply doesn't vary between experiments. In addition, the determination of the "arteriovenous" oxygen difference can be used to calculate myocardial oxygen consumption and cardiac efficiency^{16,18}.

1. Turn on the circulating water bath and set at 37 °C to warm up the perfusion apparatus.
2. Turn on the computer and the data acquisition system that will be used to measure cardiac function.
3. Connect the recording devices (pressure catheter, pressure-volume catheter, oxygen microelectrodes, flowmeters, etc.) to the data acquisition system and perform calibration of the instruments following the manufacturer's instructions.
4. Fill the buffer reservoir with ultrapure water. Turn on the peristaltic pump and flush out the water through all the tubing and glassware to rinse the system. Turn off the peristaltic pump and make sure no water stays in the tubing and/or glassware as this may affect the concentration of the perfusion buffer and the heart preparation.
5. Connect a new 1.0 µm glass fiber filter to the system. Connect the gas tank containing a mixture of carbon dioxide 5% and oxygen 95% to the oxygenating chamber.
CAUTION: The following steps involve the manipulation of radioactive material. Wear appropriate PPE and follow the safety and waste disposal regulations set by the institution's radiation safety office.
6. Fill the buffer reservoir with perfusion buffer. Turn on the pump and ensure filling of all tubing and glassware with the perfusion buffer. Run the perfusion buffer through the perfusion apparatus in the recirculating mode and oxygenate for at least 30 min prior to use.

7. Tightly attach the tube of a 20 ml syringe underneath the heart chamber to recover the coronary effluent. Connect the tip of the syringe to the top of a three-way stopcock. Connect the side arm to a 3 ml syringe. Connect the bottom arm via tubing to a container for liquid radioactive waste.

NOTE: When using the fatty acid-BSA complex, oxygenation of the perfusion buffer cannot be carried out through direct bubbling with a gas dispersion tube as this will cause excessive foaming of the solution. Use a membrane oxygenator (**Figure 1**) or a sheet flow oxygenating chamber for that purpose. It is highly recommended to verify that an appropriate level of oxygenation is reached by placing an oxygen microelectrode in the perfusion circuit (**Figure 1**).

4. Rat Heart Isolation and Cannulation

1. Weigh rat on a scale.
2. Prepare a syringe with anesthetic dose of 150 mg/kg thiobutabarbital sodium salt hydrate and a tuberculin syringe with 200 USP units heparin.
3. Inject thiobutabarbital I.P. and wait for the animal to lose consciousness. Other induction agents can be used as long as this will not interfere with the purpose of the experiment (See Choice of the anesthetic in the **Discussion Section** below).
4. Check for appropriate level of anesthesia by confirming lack of toe pinch reflex. Make sure to maintain proper depth of anesthesia to assure that the animal does not feel pain during the procedure.
5. Once the rat is fully unconscious and does not respond to toe pinch, place it on its back on the operating table and secure limbs with tape or pins.
6. Clip the abdomen free of hair and perform a midline incision of the abdomen. Do not open the chest cavity at this point yet. Move the stomach and intestine aside to reveal the inferior vena cava. Inject the heparin directly into the inferior vena cava and wait 5 to 10 sec before proceeding.
7. Using scissors cut the diaphragm and the sides of the rib cage to expose the content of the chest cavity.
8. Delicately grab the heart between the thumb, index and middle fingers and excise both heart and lungs together. Cut at the level of the descending aorta, being careful not to damage the aortic arch and ascending aorta in the process. Immediately transfer heart and lungs to one of the dissection dishes filled with ice-cold KH buffer.
9. After the heart stops beating, transfer into the second dissection dish and trim off any large pieces of lung tissue attached while keeping the heart submerged in ice-cold KH buffer. Cut the descending aorta right above the aortic arch.
CAUTION: The following steps involve the manipulation of radioactive material. Wear appropriate PPE and follow the safety and waste disposal regulations set by the institution's radiation safety office.
10. Flush the aortic line of the perfusion apparatus to fill the aortic cannula with warm buffer and to eliminate any water or air that may still be present in the tubing. Allow the perfusion buffer to drip from the aortic cannula to minimize the chance of air emboli at the time the heart is attached to the cannula.
11. Using two micro dissecting forceps carefully open the aorta and slide the heart up onto the aortic cannula. Secure the aorta on the cannula with a micro clip and initiate Langendorff perfusion of the heart. Observe the heart start beating again and expel all the blood remaining in the coronary vasculature in the seconds following the beginning of perfusion.
NOTE: It is very important to perform steps 4.6 through 4.10 as fast as possible to prevent irreversible ischemic damage to the heart. With experience, the whole procedure should take between 1 and 2 min. When sliding the aorta up on the cannula, be careful not to pass the aortic root as this may result in myocardial hypoperfusion and damage to the aortic valve.
12. Tie the aorta to the aortic cannula with a 3-0 silk suture and remove the micro clip. Locate the pulmonary vein. It may be necessary to trim the non-cardiac tissues to find it, but do not cut too much of the non-cardiac tissues as they will serve to tie the left atrium to the cannula.
13. Flush the left atrial line of the perfusion apparatus to fill the atrial cannula with warm buffer and to eliminate any water or air that may still be present in the tubing. Be particularly careful to remove any air bubble from the apparatus to minimize the chance of air emboli at the time the heart is attached to the cannula.
14. Using two micro dissecting forceps delicately grab the opening of the pulmonary vein and slide the heart up onto the atrial cannula. It may be necessary to reposition the heart by gently rotating the atrial and/or aortic cannula to accomplish this step. In any case, ensure that the procedure does not impose excessive strain on the heart and cause bending of the aorta. Tie the left atrium to the atrial cannula with a 3-0 silk suture.
15. Open the atrial line and simultaneously switch the aortic line from the Langendorff mode to the working mode. If buffer leaks out from the left atrium, close the atrial line, switch back the aortic line to Langendorff perfusion, and use another 3-0 silk suture to tie the left atrium more securely to the cannula.

5. Measurement of Cardiac Function and Sample Collection

NOTE: The determination of metabolic fluxes will require the knowledge of the coronary flow (CF). As described below, coronary flow values can be obtained with the simple use of a stopwatch. Additionally, the measurement of aortic flow (AF) with the same method will allow the determination of cardiac output ($CO = CF + AF$), which can then be used to calculate cardiac power (CP) as a general measure of cardiac function by applying the formula $CP = CO (m^3/s) * Afterload (Pa)$. Another method available for the assessment of cardiac function relies on real time measurement of pulse pressure with a pressure transducer (**Figures 3 and 4**). Although optional, the most accurate and detailed measurements of cardiac contractile function and hemodynamics, including the determination of left ventricular systolic and diastolic functions, will be achieved with the use of a pressure-volume (PV) conductance catheter. This section briefly describes the catheterization of the isolated heart. Additional information regarding the calibration of PV catheters and data analysis with statistical software can be found in references^{14,15}.
CAUTION: The following steps involve the manipulation of radioactive material. Wear appropriate PPE and follow the safety and waste disposal regulations set by the institution's radiation safety office.

1. If the experiment includes direct measurement of LV function with a catheter, puncture the LV apex with a 26 G needle and introduce the catheter via the puncture.
2. When using a pressure-volume catheter, carefully position the catheter so that its shaft is aligned with the LV longitudinal axis, with the distal electrode right below the aortic valve and adjacent to the endocardial border, and the proximal electrode just inside the ventricular wall.

3. Seal the heart into the water-jacketed heart chamber and monitor cardiac functional parameters with the data acquisition software. Start recording after baseline cardiac parameters have been stable for more than 5 min.
4. Determine the coronary flow by measuring the time required to fill the 20 ml syringe tube attached underneath the heart chamber. After the measurement, open the three-way stopcock to empty the coronary effluent into the radioactive liquid waste container.
NOTE: Flow measurements can also be performed using a flowmeter and flowprobes.
5. Use the 3 ml syringe attached to the side arm of the three-way stopcock to recover ~2 ml coronary effluent as it exits the heart. Transfer 0.5 ml of the coronary effluent into a 2 ml capless microcentrifuge tube and immediately proceed with the determination of the rates of glucose oxidation (Section 6 below).
6. Transfer the rest of the coronary effluent sample (~1.5 ml) in an appropriately labeled microcentrifuge tube and store on ice.
7. Repeat steps 5.4 to 5.6 at regular intervals (e.g. every 5 or 10 min) until the end of the perfusion experiment.
8. If using a pressure-volume catheter, inject a 10 μ l bolus of hypertonic saline (15%) into the atrial line and right before the atrial cannula before concluding the experiment. Use this bolus injection to calculate the parallel conductance (V_p), which is critical for accurate determination of cardiac volume¹⁵.
9. Unseal the heart chamber and remove the catheter from the LV if one was used in the experiment. Recover the heart using one of the following options:
 1. If there is no need to isolate specific areas of the heart for downstream analyses and if the perfusion apparatus allows it, close both atrial and aortic lines and immediately freeze-clamp the heart on its cannulas using Wollenberger tongs pre-cooled in liquid nitrogen.
 2. Alternatively, cut the heart off the cannulas and drop it into ice-cold KH buffer. Quickly dry the heart on a paper towel and measure its wet weight. The heart can then be dissected and tissue samples collected for specific measurements. Freeze the remaining tissue using Wollenberger tongs pre-cooled in liquid nitrogen.
10. Store the frozen heart tissue at -80 °C until determination of dry weight (See section 8. Calculations).

6. Determination of Myocardial Glucose Oxidation Rates

NOTE: The method consists in the quantitative recovery of $^{14}\text{CO}_2$ from the coronary effluent with a trapping solution of hydroxide of hyamine. The $^{14}\text{CO}_2$ dissolved as $\text{H}^{14}\text{CO}_3^-$ is recovered following acidification of the buffer with perchloric acid. Samples should be processed immediately after their recovery as passive diffusion of gas between air and sample will result in a loss of $^{14}\text{CO}_2$ over time. The scintillation vials should be tightly sealed with the rubber sleeve stoppers to prevent the loss of $^{14}\text{CO}_2$ after adding perchloric acid. If necessary, parafilm can be used to secure the rubber sleeve stoppers to the vials (Figure 2).

1. Add 1 ml of 10x concentrated hydroxide of hyamine to glass scintillation vials (one vial per sample + two extra vials for determination of the background activity).
CAUTION: Hydroxide of hyamine is highly toxic and causes severe burns. Consult the product MSDS for appropriate handling and storage.
2. Using tweezers delicately transfer the 2 ml capless microcentrifuge tube containing the 0.5 ml coronary effluent sample to a vial pre-filled with the hydroxide of hyamine. Use 0.5 ml perfusion buffer for the determination of the background activity.
3. Cap the vial with a rubber sleeve stopper. Parafilm may be used to secure sealing of the vial. Using a 1 ml syringe and a 23 G long needle, inject 200 μ l of perchloric acid (60% w:w%) through the rubber sleeve stopper and directly into the 2 ml capless tube.
NOTE: The coronary effluent should turn white due to the precipitation of BSA.
4. Let the vials sit overnight.
CAUTION: Perchloric acid is highly corrosive, may act as an oxidizer and/or cause an explosion hazard. Consult the product MSDS for appropriate handling and storage.
5. The next day, remove the rubber sleeve stoppers. Carefully retrieve each 2 ml capless tube with tweezers and wash the bottom of the tube on top of the open vial with 1 ml scintillation cocktail to retrieve all of the hydroxide of hyamine. Discard the capless tube in an appropriately labeled radioactive waste container.
6. Add an additional 9 ml scintillation cocktail per vial. Add 0.5 ml perfusion buffer directly to two vials filled with 10 ml liquid scintillation cocktail for the determination of the specific activity. Shake the vials vigorously by hand and wait at least 6 hr to allow air bubbles to dissipate before measuring in a liquid scintillation counter appropriately set up for dual label experiments.
NOTE: Use clear glass vials to visualize the needle when piercing the rubber sleeve stoppers. Do not drop perchloric acid into the hydroxide of hyamine as this will ruin the reaction. Adding the perchloric acid releases the $^{14}\text{CO}_2$ from the coronary effluent into the air. Although the vials should be tightly sealed and all of the $^{14}\text{CO}_2$ should be trapped into the hyamine of hydroxide, it is recommended to perform this assay under the chemical fume hood.

7. Determination of Myocardial Oleate Oxidation Rates

NOTE: The method is based on the quantitative separation and recovery of $^3\text{H}_2\text{O}$ from the coronary effluent using a strong anion exchange resin. Unlike the recovery of $^{14}\text{CO}_2$, there is no sample stability issue and the coronary effluent can be kept on ice or stored in the freezer before performing the assay.

1. Prepare anion exchange resin columns (one column per sample + two extra columns for determination of the background activity) by filling the tip of 3 ml syringe tubes with glass wool. Add the resin/water slurry with a transfer pipette until the resin reaches the 2 ml mark on the syringe tube.
2. Wash the resin by passing 2 ml ultrapure water through the column. Repeat this step two more times.
3. Place open scintillation vials under the columns and load 0.5 ml coronary effluent per column. Load 0.5 ml perfusion buffer for determination of the background activity.
4. Wash the columns successively with 0.5, 1 and 2 ml ultrapure water. Once the elution is done, discard the columns in an appropriately labeled radioactive waste container.

5. Add 13 ml liquid scintillation cocktail per scintillation vial. Add 0.5 ml perfusion buffer directly to two vials filled with 13 ml liquid scintillation cocktail for determination of the specific activity. Shake the vials vigorously and wait at least 6 hr before measuring in a liquid scintillation counter appropriately set up for dual label experiments.

8. Calculations

1. If not already done, determine the wet weight of the whole perfused heart.
NOTE: Do not allow the frozen tissue to thaw if molecular and biochemical analyses are to be subsequently performed on the remaining tissue.
2. Determine the wet weight of a tissue sample from the whole perfuse-heart (use approximately 15 to 30% of the whole heart). Place the tissue sample in an oven set at 50 °C overnight and measure its dry weight. Use the wet weight/dry weight ratio of the tissue sample to determine the dry weight of the whole heart in grams (g dry wt.).
3. For each time point x express the value of coronary flow CF_x in ml/min.
4. Determination of the rate of glucose oxidation
 1. Average the two disintegration/min (d.p.m.) values measured for the background activity of ^{14}C to determine the correction factor $^{14}C_{d.p.m.ba}$.
 2. Determine the ^{14}C averaged value of specific activity $^{14}C_{d.p.m.sa}$.
 3. Determine the specific radioactivity of glucose in d.p.m./ μ mol (F_{Glu}) by applying the formula

$$F_{Glu} = \frac{^{14}C_{d.p.m.sa}}{n_{Glu}}$$

NOTE: Where n_{Glu} (μ mol) = C_{Glu} (μ mol/L) * sample volume (L) = 2.5 when using glucose at 5 mmol/L and a 0.5 ml sample.

4. Determine for each time point x the rate of production of $^{14}CO_2$ in d.p.m./min (A) by applying the formula

$$A = \frac{^{14}C_{d.p.m.x} - ^{14}C_{d.p.m.ba}}{Vol_x} * CF_x$$

NOTE: Where Vol_x (ml) = 0.5

5. Divide A by the determined value of dry heart weight to obtain the normalized rate of production of $^{14}CO_2$ (A_{Norm}) in d.p.m./min per g dry wt.
6. Apply the formula $GO = A_{Norm}/F_{Glu}$ to obtain the rate of glucose oxidation (GO) in μ mol of glucose/min per g dry wt.

5. Determination of the Rate of Oleate Oxidation
 1. Average the two disintegration/min (d.p.m.) values measured for the background activity of 3H to determine the correction factor $^3H_{d.p.m.ba}$.
 2. Determine the 3H averaged value of specific activity $^3H_{d.p.m.sa}$.
 3. Determine the specific radioactivity of oleate in d.p.m./ μ mol (F_{Ole}) by applying the formula

$$F_{Ole} = \frac{^3H_{d.p.m.sa}}{n_{Ole}}$$

NOTE: Where n_{Ole} (μ mol) = C_{Ole} (μ mol/L) * sample volume (L) = 0.2 when using oleate at 0.4 mmol/L and a 0.5 ml sample.

4. Determine for each time point x the rate of production of 3H_2O in d.p.m./min (B) by applying the formula

$$B = \frac{^3H_{d.p.m.x} - ^3H_{d.p.m.ba}}{Vol_x} * CF_x$$

NOTE: Where Vol_x (ml) = 0.5


5. Divide B by the determined value of dry heart weight to obtain the normalized-rate of production of 3H_2O (B_{Norm}) in d.p.m./min per g dry wt.
6. Apply the formula $OO = B_{Norm}/F_{Ole}$ to obtain the rate of oleate oxidation (OO) in μ mol of oleate/min per g dry wt.

Representative Results

Two representative experiments are described in the figures below. In both cases, the heart of a 16 week old male Sprague Dawley rat was isolated and perfused in the working mode with KH buffer prepared according to the preceding protocol. In each experiment, the heart was subjected to a stress condition to affect cardiac work. Cardiac contractile function was assessed by continuous recording of pulse pressure through insertion of a pressure transducer in the aortic line and by determination of cardiac power. The consequences of each stress condition on the utilization of energy providing substrates were simultaneously determined by measurement of the rates of glucose and oleate oxidation.

In the first experiment, an acute increase in workload was simulated after 20 min perfusion at near-physiological workload by increasing the afterload by 40% (accomplished by manually raising the aortic overflow chamber) and by adding epinephrine (1 μ mol/L) to the perfusion buffer (**Figure 3A**). Heart rate, which can be determined by measuring the interval between the peak systolic pressure values on the pulse pressure trace, increased immediately by more than 50% upon workjump induction (**Figure 3B**). Cardiac power increased by more than 40% at workjump, which was accompanied by an increase in both rates of glucose and oleate oxidation (**Figure 3C**). The results show that, under the stress of an acute increase in workload, the heart rapidly adapts to increase energy generation for contraction from both glucose and fatty acid oxidation. However, the relative increase in rate of oxidation was more important for glucose (~2.8-fold) than it was for oleate (~1.3 fold). Increased reliance on carbohydrates oxidation to cope with the extra workload is a typical feature of the pressure-overloaded mammalian heart¹⁸.

fatty acid utilization post ischemia is a well-estalished feature of the reperfused heart¹⁹.



circulating water bath set at 37 °C. [Please click here to view a larger version of this figure.](#)




Figure 2: Representation of the Different Steps Involved in the Setup of the CO₂ Trap. (A) Add 1 ml of 10x concentrated hydroxide of hyamine. (B) Add a 0.5 ml sample contained in a capless tube. (C) Seal the vial. (D) Inject 200 μ l of perchloric acid (60% w:w%). [Please click here to view a larger version of this figure.](#)




Figure 3: Representative Results of a Workjump Experiment. (A) Continuous recording of pulse pressure. (B) Short interval recording depicting the change in pulse pressure at the time of workjump initiation. (C) Cardiac rates of glucose oxidation (red trace with circles) and oleate oxidation (blue trace with squares) were determined by analysis of the coronary effluent at a 5 min interval. Cardiac power (black trace with triangles) was determined by measurement of the cardiac output at the same time the coronary effluent samples were recovered. [Please click here to view a larger version of this figure.](#)




Figure 4: Representative Results of an Ischemia-reperfusion Experiment. (A) Continuous recording of pulse pressure. (B) Short interval recording depicting the recovery of contractile function during the first 5 min of reperfusion. (C) Cardiac rates of glucose oxidation (red trace with circles) and oleate oxidation (blue trace with squares) were determined by analysis of the coronary effluent at a 5 min interval, except during the first 5 min of reperfusion where analyzes were performed at a 1 min interval. Cardiac power (black trace with triangles) was determined by measurement of the cardiac output at the same time the coronary effluent samples were recovered. [Please click here to view a larger version of this figure.](#)

Discussion

The preceding protocol details the methods to simultaneously quantify the flux of substrate through glucose oxidation and fatty acid oxidation in the isolated working rat heart. The measurements can then be superimposed to the recorded cardiac functional parameters to determine the relationship between substrates metabolism and cardiac work under baseline and stress conditions (change in workload, ischemia-reperfusion, etc...). It is also possible to evaluate how the metabolism/contraction relationship is affected by preexisting conditions such as heart failure and diabetes. In addition, the heart of genetically-modified rodents can be used to interrogate the effect of a specific protein on cardiac metabolism and function. Last, the effect of drugs and other circulating factors on these parameters can be individually tested. Because the flux of glucose through glycolysis does not always correlate with the rate of glucose oxidation, it may be informative to follow the rates of glucose flux through both pathways in a single experimental setting.

The rates of glycolysis can be determined by adding [5-³H]glucose to the perfusion buffer, because the release of ³H₂O is determined by the activity of the enolase step of the glycolysis²⁰. Alternatively [2-³H]glucose, which leads to the production of ³H₂O at the phosphoglucose isomerase step of the glycolytic pathway, can be used to interrogate the rates of glucose uptake by the heart muscle^{16,17,21}. The possibility to choose from multiple radiolabeled tracers to investigate the fate of glucose at different levels of its catabolism is another example of the versatility of the technique. However, because all the flux measurements rely on the quantitative recovery of either ³H₂O or ¹⁴CO₂ from the coronary effluent, only two radiolabeled tracers (one ³H-labeled and the other one labeled with ¹⁴C) can be used in the perfusion buffer at a time.

Methodological considerations

There are some inherent limitations to the measurement of cardiac metabolic flux and function using this protocol. Although the use of KH buffer allows for a total control over the composition of the perfusate, the physiological relevance of this experimental setup may be questionable. First, the use of a crystalloid solution over blood is known to negatively impact cardiac hemodynamics and resistance to ischemia^{22,23}. Second, the perfusion buffer we describe here lacks a variety of hormones and nutrients that can directly modulate cardiac metabolism and consequently impact the heart's response to a simulated stress condition. Indeed, the mammalian heart is a metabolic omnivore and can, besides glucose and fatty acids, utilize other substrates to fulfill its energy requirements (lactate, pyruvate, ketone bodies, branched-chain amino acids). There is mounting evidence that some of these substrates play an important role in the metabolic remodeling of the diseased heart^{24,25}. It is entirely possible for the investigator to add these substrates to the perfusion buffer, to modulate their concentration in order to mimic more closely different physiological conditions (e.g. fed state versus fasted state) or disease states, and to follow their rates of oxidation using the appropriate radiolabeled tracers^{26,27}. The metabolism of triglycerides can also be traced, and in that case it is recommended to avoid the use of heparin prior to excision of the heart as this will induce the release of lipoprotein lipase from the endothelium and significantly decrease the extraction of triglyceride from the buffer²⁸. With careful selection of the radiolabeled tracers, the incorporation of radioactivity in various tissue metabolites can also be measured after perfusion to determine parameters such as *de novo* triglyceride synthesis, glycogen turnover, or rates of protein synthesis^{18,29,30}. In other words, the investigator can work with a wide variety of substrates/hormones combinations and concentrations. The choice of the buffer composition will mostly depend on the objectives of the experiment. Because these controlled buffer conditions create a "simplified" physiological model, results from *ex vivo* working heart perfusion experiments should be interpreted with caution and if possible the data should be further validated *in vivo*.

Choice of the anesthetic

The anesthetic used on rats prior to excision of the heart should be carefully selected based on its known effects on cardiopulmonary function and metabolism to ensure that this will not interfere with the experiment to be performed. Both injectable and inhalational anesthetics rapidly induce hyperglycemia and variable degrees of glucose intolerance that may affect cardiac metabolism during perfusion^{31,32}. Compared to other agents, the short-term effects of barbiturates (Pentobarbital and thiobutabarbitol) on glucose homeostasis are relatively negligible³¹. However, intraperitoneal pentobarbital anesthesia prior to heart excision has been shown to decrease cardiac output, impair left ventricular function, and increase myocardial lactate release in an *ex vivo* protocol of ischemia-reperfusion³³. The negative inotropic effect that pentobarbital has on the isolated rat heart is suggested to be caused by tissue accumulation of the drug³⁴. Conversely the use of inhalational anesthetics, which are more rapidly washed out from the cardiac tissue, is associated with better contractile function *ex vivo*³³. Volatile anesthetics may actually provide cardioprotection during ischemia-reperfusion through a mechanism involving the opening of the mitochondrial K_{ATP} channels and increased binding of hexokinase to mitochondria³². In summary, the type of anesthetic used in an isolated working heart perfusion protocol is a significant variable in the assessment of both functional and metabolic parameters that may directly impact the outcomes of the experiment. Therefore, the type and the dose of anesthetic used should always be reported in the methods section of an experiment, and these parameters should not be changed between experiments that are meant to be compared.

Radioisotopes in heart perfusion

All flux measurements performed with the preceding protocol are performed in the non-recirculating mode, meaning that the coronary effluent is discarded instead of being returned to the buffer reservoir (**Figure 1**). The investigator may rather choose to use the perfusion apparatus in the recirculating mode, which has the advantage of requiring a much smaller volume of buffer and hence radioactivity to operate. However, recycling of the coronary effluent compromises the steady state composition of the perfusion buffer through recovery of byproducts originating from the metabolic activity of the heart (including lactate, but also ³H₂O and H¹⁴CO₃-), which complicates the determination of metabolic fluxes and may even alter cardiac function over time³⁵. These issues are prevented in the non-recirculating mode. Due to the amount of radioactivity and to the large volume of perfusion buffer used in a single experiment, the investigator should be particularly cautious when using the working rat heart in metabolic flux analyses. When using a perfusion apparatus for the first time, it is recommended to perform several mock experiments with non-radioactive buffer to become familiar with the different steps of the protocol and with the safety procedures. The mounting of the heart on the cannulas is a particularly sensitive step because it requires establishing a close contact with the apparatus and because buffer may leak or shoot out from one of the heart's severed blood vessels. The perfusion apparatus described by Taegtmeier and colleagues¹¹ has the advantage of including a Langendorff reservoir that is entirely independent from the rest of the perfusion apparatus, and can therefore be filled with non-radioactive KH buffer to prevent spills of radioactive material during the heart's cannulation. Regardless of the system used, the experiments

should be performed in a dedicated area with restricted access. The room should include a sink and a supply of ultrapure water to perform buffer preparation and cleaning of contaminated equipment in the same area. Investigators should work closely with their institution's radiation safety office to establish specific containment, control and decontamination procedures.

Cleaning of the perfusion apparatus

The post experimental cleaning of the perfusion apparatus is a critical step that is too often overlooked and, if not carefully executed, responsible for most of the issues related to poor experimental reproducibility. The nutrient-rich perfusion buffer and the high temperature of the perfusion system provide ideal conditions for bacterial and fungal growth. The utilization of proteins (insulin, BSA) and fatty acids in the perfusion buffer adds another degree of complexity to the cleaning procedure because these compounds will stick to the surface of the tubing and glassware, making them hard to flush out of the apparatus. The use of radioisotopes will also impose additional constraints such as the creation of a dedicated containment area in the laboratory for manipulation of the contaminated equipment and disposal of solid and liquid radioactive wastes. Therefore, the adequate cleaning procedure will mostly depend on both the composition of the perfusion buffer and on the type of perfusion apparatus used. If using a commercial apparatus, check the manufacturer's website or contact the customer service to obtain information on how to perform cleaning without damaging any of the components of the apparatus. In general, all glassware and plastic parts can be washed with a wide range of soaps. Enzyme-active powered detergents are particularly useful to remove fatty acid-BSA residue. Most contaminants will also be removed by running 0.1 M HCl or 0.1 M HNO₃ through the apparatus for several hours. We obtain satisfactory cleaning results by flushing the system first with 0.1 M HCl, then with a fresh 1% (w:v) solution of enzyme-active powered detergent prepared in warm water, and finally by rinsing the system with ultrapure water. When using a custom-built perfusion apparatus as the one originally described by Taegtmeyer and colleagues¹, it may be easier and more effective to completely dismantle the apparatus at the end of each experimental day. The glassware is cleaned by a 15 min immersion into a concentrated bath of a chromic acid and sulfuric acid mixture. The plastic parts and the PVC tubing can be washed with a residue-free detergent. We found it is actually faster and more reliable to entirely replace the PVC tubing every day, because it limits the manipulation of material contaminated by radiochemicals and because it prevents leaving residues of cleaning agents behind. In any case, the investigator should apply the following rules: 1- Clean the perfusion apparatus and all dirty equipment immediately after completing the perfusion experiment. Waiting will only make the cleaning more difficult and time consuming. 2- Check the circulating bath of the water jacket system regularly for contaminations. Use of a water conditioner will increase the interval between cleaning of the water bath. 3- After cleaning, thoroughly rinse all glassware and tubing with tap water several times and finish rinsing with ultrapure water to remove residues from cleaning agents. 4- Two heart preparations consecutively failing when the dissection was carefully executed and the perfusion buffer carefully prepared are likely to indicate a contamination of the apparatus (either by bacteria or by solvent residues). If this happens, the washing and rinsing procedures should be entirely repeated.

Scaling down to the mouse heart

Although the preceding protocol focuses on the determination of metabolic rates in an isolated working rat heart, the same procedures can be applied to the mouse heart with a few modifications to the perfusion apparatus and data acquisition equipment³⁶. Due to its smaller size the isolated working mouse heart is technically more challenging, but because of its significantly lower flow rate it has the advantage of requiring a much lower volume of perfusion buffer. The large number of genetically modified mouse models that are already available also makes the isolated working mouse heart very attractive to study the function of a single gene product on cardiac metabolic and functional remodeling. However, the recent technological advances in genome editing and a rapidly growing catalog of transgenic and knockout rats are rapidly closing the gap between the two rodent species. Moreover, the rat has long been praised as a superior animal model to investigate cardiovascular disease because its pathophysiology closely mimics human conditions³⁷. For these reasons, we believe that the isolated working rat heart still hold an important place in the modern era of cardiovascular research.

Disclosures

The authors declare that they have no competing financial interests.

Acknowledgements

This work was supported by National Institutes of Health Grants R00 HL112952 (to R. H.), R01 HL108618 (to J.P.G.), P01 HL051971, and P20 GM104357. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

1. Neely, J. R., & Morgan, H. E. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. *Annu Rev Physiol.* **36**, 413-459 (1974).
2. Sen, S. *et al.* Glucose regulation of load-induced mTOR signaling and ER stress in mammalian heart. *J Am Heart Assoc.* **2**, e004796 (2013).
3. Young, M. E., McNulty, P., & Taegtmeyer, H. Adaptation and maladaptation of the heart in diabetes: Part II: potential mechanisms. *Circulation* **105**, 1861-1870 (2002).
4. Stanley, W. C., Recchia, F. A., & Lopaschuk, G. D. Myocardial substrate metabolism in the normal and failing heart. *Physiol Rev.* **85**, 1093-1129 (2005).
5. Fillmore, N., & Lopaschuk, G. D. Targeting mitochondrial oxidative metabolism as an approach to treat heart failure. *Biochim Biophys Acta.* **1833**, 857-865 (2013).
6. Jaswal, J. S., Keung, W., Wang, W., Ussher, J. R., & Lopaschuk, G. D. Targeting fatty acid and carbohydrate oxidation--a novel therapeutic intervention in the ischemic and failing heart. *Biochim Biophys Acta.* **1813**, 1333-1350 (2011).
7. Taegtmeyer, H. Cardiac metabolism as a target for the treatment of heart failure. *Circulation.* **110**, 894-896 (2004).
8. Taegtmeyer, H. *et al.* Assessing Cardiac Metabolism: A Scientific Statement From the American Heart Association. *Circ Res.* (2016).

9. Barr, R. L., & Lopaschuk, G. D. Methodology for measuring in vitro/ex vivo cardiac energy metabolism. *J Pharmacol Toxicol Methods*. **43**, 141-152 (2000).
10. Neely, J. R., Liebermeister, H., Battersby, E. J., & Morgan, H. E. Effect of pressure development on oxygen consumption by isolated rat heart. *Am J Physiol*. **212**, 804-814 (1967).
11. Taegtmeyer, H., Hems, R., & Krebs, H. A. Utilization of energy-providing substrates in the isolated working rat heart. *Biochem J*. **186**, 701-711 (1980).
12. Liao, R., Podesser, B. K., & Lim, C. C. The continuing evolution of the Langendorff and ejecting murine heart: new advances in cardiac phenotyping. *Am J Physiol Heart Circ Physiol*. **303**, H156-167 (2012).
13. Cingolani, O. H., & Kass, D. A. Pressure-volume relation analysis of mouse ventricular function. *Am J Physiol Heart Circ Physiol*. **301**, H2198-2206 (2011).
14. Pacher, P., Nagayama, T., Mukhopadhyay, P., Batkai, S., & Kass, D. A. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. *Nat Protoc*. **3**, 1422-1434 (2008).
15. Abraham, D., & Mao, L. Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice. *J Vis Exp*. (2015).
16. Harmancey, R. *et al.* Insulin resistance improves metabolic and contractile efficiency in stressed rat heart. *FASEB J*. **26**, 3118-3126 (2012).
17. Harmancey, R., Vazquez, H. G., Guthrie, P. H., & Taegtmeyer, H. Decreased long-chain fatty acid oxidation impairs postischemic recovery of the insulin-resistant rat heart. *FASEB J*. **27**, 3966-3978 (2013).
18. Goodwin, G. W., Taylor, C. S., & Taegtmeyer, H. Regulation of energy metabolism of the heart during acute increase in heart work. *J Biol Chem*. **273**, 29530-29539 (1998).
19. Lopaschuk, G. D., Ussher, J. R., Folmes, C. D., Jaswal, J. S., & Stanley, W. C. Myocardial fatty acid metabolism in health and disease. *Physiol Rev*. **90**, 207-258 (2010).
20. Neely, J. R., Denton, R. M., England, P. J., & Randle, P. J. The effects of increased heart work on the tricarboxylate cycle and its interactions with glycolysis in the perfused rat heart. *Biochem J*. **128**, 147-159 (1972).
21. Katz, J., & Dunn, A. Glucose-2-t as a tracer for glucose metabolism. *Biochemistry*. **6**, 1-5 (1967).
22. Gillis, A. M., Kulisz, E., & Mathison, H. J. Cardiac electrophysiological variables in blood-perfused and buffer-perfused, isolated, working rabbit heart. *Am J Physiol*. **271**, H784-789 (1996).
23. Qiu, Y., & Hearse, D. J. Comparison of ischemic vulnerability and responsiveness to cardioplegic protection in crystalloid-perfused versus blood-perfused hearts. *J Thorac Cardiovasc Surg*. **103**, 960-968 (1992).
24. Cotter, D. G., Schugar, R. C., & Crawford, P. A. Ketone body metabolism and cardiovascular disease. *Am J Physiol Heart Circ Physiol*. **304**, H1060-1076 (2013).
25. Huang, Y., Zhou, M., Sun, H., & Wang, Y. Branched-chain amino acid metabolism in heart disease: an epiphenomenon or a real culprit? *Cardiovasc Res*. **90**, 220-223 (2011).
26. Buse, M. G., Biggers, J. F., Friderici, K. H., & Buse, J. F. Oxidation of branched chain amino acids by isolated hearts and diaphragms of the rat. The effect of fatty acids, glucose, and pyruvate respiration. *J Biol Chem*. **247**, 8085-8096 (1972).
27. Liepinsh, E. *et al.* The heart is better protected against myocardial infarction in the fed state compared to the fasted state. *Metabolism*. **63**, 127-136 (2014).
28. Niu, Y. G., Hauton, D., & Evans, R. D. Utilization of triacylglycerol-rich lipoproteins by the working rat heart: routes of uptake and metabolic fates. *J Physiol*. **558**, 225-237 (2004).
29. Goodwin, G. W., Arteaga, J. R., & Taegtmeyer, H. Glycogen turnover in the isolated working rat heart. *J Biol Chem*. **270**, 9234-9240 (1995).
30. Sender, P. M., & Garlick, P. J. Synthesis rates of protein in the Langendorff-perfused rat heart in the presence and absence of insulin, and in the working heart. *Biochem J*. **132**, 603-608 (1973).
31. Hindlycke, M., & Jansson, L. Glucose tolerance and pancreatic islet blood flow in rats after intraperitoneal administration of different anesthetic drugs. *Ups J Med Sci*. **97**, 27-35 (1992).
32. Zuurbier, C. J., Keijzers, P. J., Koeman, A., Van Wezel, H. B., & Hollmann, M. W. Anesthesia's effects on plasma glucose and insulin and cardiac hexokinase at similar hemodynamics and without major surgical stress in fed rats. *Anesth Analg*. **106**, 135-142, table of contents (2008).
33. Oguchi, T., Kashimoto, S., Yamaguchi, T., Nakamura, T., & Kumazawa, T. Is pentobarbital appropriate for basal anesthesia in the working rat heart model? *J Pharmacol Toxicol Methods*. **29**, 37-43 (1993).
34. Segal, J., Schwalb, H., Shmorak, V., & Uretzky, G. Effect of anesthesia on cardiac function and response in the perfused rat heart. *J Mol Cell Cardiol*. **22**, 1317-1324 (1990).
35. Webster, I., Smith, A., Lochner, A., & Huisamen, B. Sanguinarine non- versus re-circulation during isolated heart perfusion--a Jekyll and Hyde effect? *Cardiovasc Drugs Ther*. **28**, 489-491 (2014).
36. Belke, D. D., Larsen, T. S., Lopaschuk, G. D., & Severson, D. L. Glucose and fatty acid metabolism in the isolated working mouse heart. *Am J Physiol*. **277**, R1210-1217 (1999).
37. Iannaccone, P. M., & Jacob, H. J. Rats! *Dis Model Mech*. **2**, 206-210 (2009).